UBS raises target for uniQure stock from USD 27 to USD 48

Published on 10/20/2026 at 13:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UBS began coverage with a Buy rating on October 14, 2026. uniQure stock costs EUR 19.76 on October 20, 2026, against a USD 48.00 target.

Analyst target and clinical evidence

UBS set a USD 48.00 price target on October 14, 2026.
AMT-130 showed 44 percent slowing at 48 months on September 29, 2026.
uniQure stock traded at EUR 19.76 at 1:34 p.m. CEST at Lang & Schwarz on October 20, 2026.

QURE, NL0010696654, Illustration mit AI erstellt.

uniQure (ISIN NL0010696654) received a higher USD 48.00 price target from UBS, up from USD 27.00, in a report dated October 14, 2026, according to Markets Insider. At 1:34 p.m. CEST on October 20, 2026, the stock traded at EUR 19.76 at Lang & Schwarz.

UBS raises target to USD 48

UBS initiated coverage with a Buy rating and set its target at USD 48.00, compared with the previous USD 27.00 target cited in the October 14 report. The revision puts the analyst view well above the current euro quotation, but the currencies are different and no direct percentage comparison is appropriate.

Three milestones shape QURE

On July 29, 2026, uniQure reported second-quarter revenue of USD 5.84 million and a GAAP net loss of USD 81.06 million, according to Markets Insider. On September 29, 2026, the company reported that AMT-130 showed 44 percent slowing of disease progression at 48 months in 12 high-dose patients, while the Total Functional Capacity measure showed 61 percent slowing, according to uniQure. UBS then set its USD 48.00 target on October 14, 2026.

What does the target imply?

The target gives investors a concrete valuation marker, while the clinical record remains mixed. The 44 percent cUHDRS result did not reach statistical significance, with a p-value of 0.144, whereas the 61 percent TFC result carried a nominal p-value of 0.008, according to the company release dated September 29, 2026.

Next date is November 9

uniQure is expected to report third-quarter 2026 results on November 9, 2026, before the US market opens, according to MarketBeat. The published estimate calls for revenue of USD 6.18 million and a loss of USD 0.92 per share.

Stock price and clinical risk

The immediate investor debate combines UBS's higher target with the uncertainty around AMT-130's long-term evidence. The October 20 euro quotation provides the market reference, while the next results date offers the next scheduled company-specific checkpoint.

The stock traded at EUR 19.76 at Lang & Schwarz on October 20, 2026 at 1:34 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of uniQure stock.